Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Autore principale: | Akter, Anika |
---|---|
Altri autori: | Alam, Marzia |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
Brac University
2022
|
Soggetti: | |
Accesso online: | http://hdl.handle.net/10361/17039 |
Documenti analoghi
-
Biologics and Biosimilars as Treatment Options for Psoriasis
di: Moya, Amena Khatun
Pubblicazione: (2023) -
Importance of biologics in rheumatoid arthritis management
di: Riyadh, S. M.
Pubblicazione: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
di: Afroza, Halima
Pubblicazione: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
di: Mehreen, Elnaj
Pubblicazione: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
di: Islam, Nahidul
Pubblicazione: (2023)